A Pilot Study of Bendamustine and Rituximab Alternating With Cytarabine and Rituximab for Untreated Mantle Cell Lymphoma

Trial Profile

A Pilot Study of Bendamustine and Rituximab Alternating With Cytarabine and Rituximab for Untreated Mantle Cell Lymphoma

Recruiting
Phase of Trial: Phase I

Latest Information Update: 08 Feb 2017

At a glance

  • Drugs Bendamustine (Primary) ; Cytarabine (Primary) ; Pegfilgrastim; Rituximab
  • Indications Mantle-cell lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 18 Apr 2016 Planned End Date changed from 1 May 2023 to 1 Apr 2023.
    • 18 Apr 2016 Planned primary completion date changed from 1 Oct 2018 to 1 Sep 2018.
    • 18 Apr 2016 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top